Anthony S Stein Selected Research

blinatumomab

11/2022	The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
2/2022	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
6/2021	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
1/2021	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
1/2021	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
1/2021	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
1/2020	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
12/2019	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
10/2019	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
1/2019	Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony S Stein Research Topics

Disease

22	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 01/2005
22	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 02/2003
9	Neoplasms (Cancer) 10/2022 - 01/2005
8	Philadelphia Chromosome 01/2021 - 01/2005
7	Residual Neoplasm 02/2022 - 06/2016
5	Leukemia 10/2019 - 02/2003
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 11/2006
4	Cytokine Release Syndrome 06/2021 - 10/2018
4	Primary Myelofibrosis (Myelosclerosis) 01/2020 - 11/2006
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2019
2	Hypoalbuminemia 10/2022 - 01/2019
2	Infections 01/2021 - 10/2018
2	Thrombocytopenia (Thrombopenia) 01/2019 - 02/2003
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2017 - 04/2015
1	Blast Crisis (Blast Phase) 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Pathologic Complete Response 01/2022
1	Bites and Stings (Sting) 01/2021
1	Febrile Neutropenia 01/2021
1	Necrobiotic Disorders (Necrobiosis) 01/2020
1	Pulmonary Hypertension 01/2020
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2019
1	Invasive Fungal Infections 12/2019
1	Neutropenia 12/2019
1	Lymphoma (Lymphomas) 01/2019
1	Edema (Dropsy) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 10/2018
1	Cytopenia 10/2018
1	Myeloid Sarcoma (Chloroma) 08/2014
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2005
1	Leukopenia 02/2003
1	Fever (Fevers) 02/2003

Drug/Important Bio-Agent (IBA)

16	blinatumomabIBA 11/2022 - 01/2016
8	venetoclaxIBA 01/2021 - 01/2018
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 02/2003
3	enasidenibIBA 01/2021 - 01/2019
3	ivosidenibIBA 01/2021 - 01/2020
2	tagraxofuspIBA 10/2022 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2019
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 06/2018
2	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 01/2019
2	Clofarabine (Clolar)FDA Link 04/2015 - 03/2012
1	Transaminases (Aminotransferases)IBA 10/2022
1	Alanine (L-Alanine)FDA Link 10/2022
1	Aspartic Acid (Aspartate)FDA Link 10/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	CytokinesIBA 06/2021
1	EnzymesIBA 01/2021
1	fms-Like Tyrosine Kinase 3IBA 07/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Cadherins (E-Cadherin)IBA 01/2020
1	PNC-27IBA 01/2020
1	Cell Surface ReceptorsIBA 12/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 01/2019
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2019
1	ibrutinibIBA 01/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	vadastuximab talirineIBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Inotuzumab OzogamicinIBA 06/2017
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2015
1	Melphalan (Alkeran)FDA LinkGeneric 03/2012
1	Tacrolimus (Prograf)FDA LinkGeneric 02/2010
1	Sirolimus (Rapamycin)FDA Link 02/2010
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2006
1	Methotrexate (Mexate)FDA LinkGeneric 11/2006
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2005
1	Interleukin-2 (IL2)IBA 02/2003
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 02/2003

Therapy/Procedure

18	Therapeutics 02/2022 - 02/2017
9	Drug Therapy (Chemotherapy) 11/2022 - 01/2005
9	Cell Transplantation 01/2022 - 11/2006
5	Stem Cell Transplantation 12/2019 - 02/2003
4	Salvage Therapy 12/2019 - 01/2015
3	Homologous Transplantation 01/2022 - 02/2003
3	Transplantation 01/2022 - 01/2019
3	Immunotherapy 01/2019 - 02/2003
1	Lymphatic Irradiation 01/2022
1	Intravenous Infusions 01/2019
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Radiotherapy 08/2014
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 11/2009
1	Chemoradiotherapy 01/2005